Supplemental Table 2. Activity of ASO targeting RBD or BCL-xL in B16F10, A375 and 132N1 cells

<b>ABSTRACT</b> <b>Aims</b>: To investigate the distribution, tolerance, and anticancer/antiviral activity of Zn-based physiometacomposites (PMCs).<b> Methods</b>: Manganese, iron, nickel and cobalt doped ZnO, ZnS or ZnSe were synthesized. Cell uptake, distribution into 3-D culture and mice, biochemical and chemotherapeutic activity were studied by fluorescence/bioluminescence, confocal microscopy, flow cytometry, viability, antitumor and virus titer assays. <b>Results: </b>Luminescence and inductively coupled plasma mass spectrometry analysis showed that nanoparticle distribution was liver&gt;spleen&gt;kidney&gt;lung&gt;brain, without tissue or blood pathology. Photophysical characterization as <i>ex vivo</i> tissue probes and LL37 peptide, antisense oligomer (ASO) or aptamer delivery targeting RAS/RBD. 25 µg/ml 48-hour treatment showed &gt;98-99% cell viability, 3-D organoid uptake, 3-log inhibition of β-Galactosidase and porcine reproductive respiratory virus infection. <b>Conclusions:</b> Data support the preclinical development of PMCs for imaging and delivery targeting cancer and infectious disease. <b></b>